# A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT03034915** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2696 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** UMEC/VI 62.5/25 mcg via ELLIPTA
- **DRUG:** UMEC 62.5 mcg via ELLIPTA
- **DRUG:** Salmeterol 50 mcg via DISKUS
- **DRUG:** Placebo via ELLIPTA
- **DRUG:** Placebo via DISKUS

## Key facts

- **NCT ID:** NCT03034915
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-16
- **Primary completion:** 2018-06-18
- **Final completion:** 2018-06-18
- **Target enrollment:** 2696 (ACTUAL)
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03034915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03034915, "A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03034915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*